Recent findings indicate that EGFR-targeting ASO exhibits a more potent anti-cancer effect than traditional TKIs in NSCLC with EGFR mutations, including L858R and T790M, and can effectively suppress TKI-resistant patient-derived tumors [54]. The gene discussed is EGFR; the disease is cancer.